Neurogene Adjusts Clinical Trial After Setback

TipRanksNov 21 16:30 ET

Express News | Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome

ReutersNov 21 16:12 ET

Express News | Neurogene Inc - FDA Allows Neurogene to Proceed With Phase 1/2 Trial Using 1E15 Vg Dose

ReutersNov 21 16:05 ET

Express News | Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies

ReutersNov 21 16:05 ET

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46

Moomoo NewsNov 21 08:31 ET · Ratings

Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60

ReutersNov 21 07:21 ET